Advertisement

Psychopharmacology

, Volume 99, Issue 1, pp 40–47 | Cite as

A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA

  • Lisa H. Gold
  • Carol B. Hubner
  • George F. Koob
Original Investigations

Abstract

Methylenedioxymethamphetamine (MDMA) is a phenylethylamine with a chemical structure that resembles both the amphetamines and mescaline and has both stimulant and perception altering properties. The stimulant properties of MDMA were assessed in photocell cages designed to measure locomotor activity in rats. MDMA, over a range of doses (2.5–10.0 mg/kg, SC) produced locomotor hyperactivity which lasted up to 4 h. Further studies examined the role of the mesolimbic dopamine system in the hyperactivity induced by MDMA. 6-Hydroxydopamine lesions of the Nucleus accumbens attenuated the locomotor response produced by MDMA. The well characterized attenuation of the locomotor response produced by amphetamine was also demonstrated in the same rats. The present study demonstrates similarities in the stimulant properties of MDMA and amphetamine, and also suggests that as with amphetamine, the locomotor activation associated with MDMA may involve the presynaptic release of dopamine in the region of the Nucleus accumbens. However, MDMA may have a more unusual pharmacological profile because of its longer duration of action, neurotoxic potential, and differences in the qualitative aspects of its psychoactive effects.

Key words

Methylenedioxymethamphetamine MDMA Nucleus accumbens Locomotor activity Mesolimbic dopamine 6-Hydroxydopamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barnes D (1988) New data intensify the agony over Ecstasy. Science 239:864–866Google Scholar
  2. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, De Souza EB (1987) 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242:911–916Google Scholar
  3. Battaglia G, Brooks B, Kulsakdinum C, De Souza EB (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149:159–163Google Scholar
  4. Beardsley P, Balster R, Harris L (1986) Self-administration of methylenedioxymethamphetamine (MDMA) by Rhesus monkeys. Drug Alcohol Depend 18:149–157Google Scholar
  5. Beck J, Morgan P (1986) Designer drug confusion: a focus on MDMA. J Drug Educ 16:287–302Google Scholar
  6. Bloom FE, Algeri S, Gropetti A, Revuelta A, Costa E (1969) Lesions of central norepinephrine terminals with 6-OH-dopamine: biochemistry and fine structure. Science 166:1284–1286Google Scholar
  7. Braun U, Shulgin A, Braun G (1980) Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine). J Pharm Sci 69:192–195Google Scholar
  8. Callahan PM, Appel JB (1987) Differences in the stimulus properties of MDA and MDMA in animals trained to discriminate hallucinogens from saline. Soc Neurosci Abstr 13:1720Google Scholar
  9. Clarke PBS, Jakubovic A, Fibiger HC (1988) Anatomical analysis of the involvement of mesolimbocortical dopamine in the locomotor stimulant actions ofd-amphetamine and apomorphine. Psychopharmacology 96:511–520Google Scholar
  10. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS (1987) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241:338–345Google Scholar
  11. Creese I, Iversen SD (1975) The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Res 83:419–436Google Scholar
  12. Dowling GP, McDonough ET, Bost RO (1987) “Eve” and “Ecstasu” A report of five deaths associated with the use of MDEA and MDMA. JAMA 257:11615–1617Google Scholar
  13. Felice L, Felice J, Kissinger P (1978) Determination of catecholamines in rat brain parts by reverse-phase ion-pair liquid chromatography. J Neuorchem 31:1461–1465Google Scholar
  14. File SJ (1981) Pharmacological manipulations of responses to novelty and their habituation. In: Cooper SJ (ed) Theory in psychopharmacology, vol 1. Academic Press, London, pp 197–232Google Scholar
  15. Fishman RHB, Feigenbaum JJ, Yanai J, Klawans HL (1983) The relative importance of dopamine and norepinephrine in mediating locomotor activity. Prog Neurobiol 20:55–88Google Scholar
  16. Geyer MA, Puerto A, Menkes DB, Segal DS, Mandell AJ (1976) Behavioral studies following lesions of the mesolimbic and mesostriatal serotonergic pathways. Brain Res 106:257–270Google Scholar
  17. Geyer MA, Masten VL, Segal DS (1986) Behavioral effects of xylamine-induced depletions of brain norepinephrine: interaction with amphetamine. Behav Brain Res 21:55–64Google Scholar
  18. Glennon RA, Yousif M, Patrick G (1988) Stimulus properties of I-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs. Pharmacol Biochem Behav 29:443–449Google Scholar
  19. Gold LH, Koob GF (1988) Methysergide potentiates the hyperactivity produced by MDMA in rats. Pharmacol Biochem Behav 29:645–648Google Scholar
  20. Gold LH, Koob GF, Geyer MA (1988) Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine (MDMA) and N-ethyl-3,4-methylenedioxyamphetamine (MDE) in rats. J Pharmacol Exp Ther 247:547–555Google Scholar
  21. Grinspoon L, Bakalar J (1986) Can drugs be used to enhance the psychotherapeutic process? Am J Psychother XL:393–404Google Scholar
  22. Herve D, Studler JM, Blanc G, Glowinski J, Tassin JP (1986) Partial protection by desmethylimipramine of the mesocortical dopamine neruones from the neurotoxic effect of 6-hydroxydopamine injected in ventral mesencephalic tegmentum. The role of noradrenergic innervation. Brain Res 383:47–53Google Scholar
  23. Hollister AG, Breese C, Moreton Kuhn C, Cooper B, Schanberg S (1976) An inhibitory role for brain serotonin-containing systems in the locomotor effects ofd-amphetamine. J Pharmacol Exp Ther 198:12–22Google Scholar
  24. Hubner CB, Bird M, Rassnick S, Kornetsky C (1988) The threshold lowering effects of MDMA (ecstasy) on brain-stimulation reward. Psychopharmacology 95:49–51Google Scholar
  25. Johnson MP, Hoffman AJ, Nichols DE (1986) Effects of the enantiomers of MDA, MDMA and related analogues on [3H] serotonin and [3H] dopamine release from superfused rat brain slices. Eur J Pharmacol 132:269–276Google Scholar
  26. Joyce EM, Koob GF (1981) Amphetamine-, scopolamine-, and caffeine-induced locomotor activity following 6-hydroxydopamine lesions of the mesolimbic dopamine system. Psychopharmacology 73:311–313Google Scholar
  27. Kelly PH, Iversen SD (1976) Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol 40:45–56Google Scholar
  28. Kelly PH, Seviour P, Iversen SD (1975) Amphetamine and apomorphine response in the rat following 6-OHDA lesions of the Nucleus accumbens septi and corpus striatum. Brain Res 94:507–522Google Scholar
  29. Lamb R, Griffiths R (1987) Self-injection ofd-1-3,4-methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology 91:268–272Google Scholar
  30. Li A, Marek G, Vosmer G, Seiden L (1986) MDMA-induced serotonin depletion potentiates the psychomotor stimulant effects of MDMA on rats performing on the differential-reinforcement of-low-rate (DRL) schedule. Soc Neurosci Abstr 12:609Google Scholar
  31. Mokler DJ, Robinson SE, Rosecrans JA (1987) (±)3,4-Methylenedioxymethamphetamine (MDMA) produces long-term reductions in brain 5-hydroxytryptamine in rats. Eur J Pharmacol 138:265–268Google Scholar
  32. Nichols DE, Lloyd DH, Hoffman AJ, Nichols MB, Yim GKW (1982) Effects of certain hallucinogenic amphetamine analogues on the release of [3H] serotonin from rat brain synaptosomes. J Med Chem 25:530–535Google Scholar
  33. Nichols DE, Hoffman AJ, Oberlender RA, Jacob P, Shulgin AT (1986) Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J Med Chem 29:2009–2015Google Scholar
  34. Oberlender R, Nichols DE (1988) Drug discrimination studies with MDMA and amphetamine. Psychopharmacology 95:71–76Google Scholar
  35. Onn S-P, Berger T, Stricker EM, Zigmond MJ (1986) Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: histochemical and neurochemical analysis. Brain Res 376:8–19Google Scholar
  36. Peroutka S (1987) Incidence of recreational use of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) on an undergraduate campus. New Engl J Med 317:1542–1543Google Scholar
  37. Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1:273–277Google Scholar
  38. Pettit HO, Ettenberg A, Bloom FE, Koob GF (1984) Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology 84:167–173Google Scholar
  39. Roberts DC, Koob GF, Klonoff P, Fibiger HC (1980) Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the Nucleus accumbens. Pharmacol Biochem Behav 12:781–787Google Scholar
  40. Roberts DCS, Zis AP, Fibiger HC (1975) Ascending catecholamine pathways and amphetamine-induced locomotor activity: importance of dopamine and apparent non-involvement of norepinephrine. Brain Res 93:441–454Google Scholar
  41. Sachs C, Jonsson G (1975) Mechanisms of action of 6-hydroxydopamine. Biochem Pharmacol 24:1–8Google Scholar
  42. Schechter M (1986) Discriminative profile of MDMA. Pharmacol Biochem Behav 24:1533–1537Google Scholar
  43. Schmidt C (1987a) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 240:1–7Google Scholar
  44. Schmidt C (1987b) Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs. Eur J Pharmacol 136:81–88Google Scholar
  45. Schmidt CJ, Wu L, Lovenberg W (1986) Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur J Pharmacol 124:175–178Google Scholar
  46. Schmidt CJ, Levin JA, Lovenberg W (1987) In vitro and in vivo neurochemical effects of MDMA on striatal monoaminergic systems in rat brain. Biochem Pharmacol 36:747–755Google Scholar
  47. Shulgin AT, Nichols DE (1978) Characterization of three new psychotomimetics. In: Stillman RC, Willette RE (eds) The pharmacology of hallucinogens. Pergamon Press, New York, pp 74–83Google Scholar
  48. Steele TD, Nichols DE, Yim GK (1987) Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 36:2297–2303Google Scholar
  49. Stone D, Stahl D, Hanson G, Gibb J (1986) The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 128:41–48Google Scholar
  50. Stone DM, Johnson M, Hanson GR, Gibb JW (1988) Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine J Pharmacol Exp Ther 247:79–87Google Scholar
  51. Swanson LW, Hartman BK (1975) The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-β-hydroxylase as a marker. J Comp Neurol 163:467–506Google Scholar
  52. Swerdlow NR, Vaccarino FJ, Amalric M, Koob GF (1986) The neural substrates for the motor-activating properties of psychostimulants: a review of recent findings. Pharmacol Biochem Behav 25:233–248Google Scholar
  53. Tassin JP, Simon H, Herve D, Blanc G, Le Moal M, Glowinski J, Bockaert J (1982) Non-dopaminergic fibres may regulate dopamine-sensitive adenylate cyclase in the prefrontal cortex and Nucleus accumbens. Nature 295:696–698Google Scholar
  54. Thornbrug JE, Moore KE (1973) The relative importance of dopaminergic and noradrenergic neuronal systems for the stimulation of locomotor activity induced by amphetamine and other drugs. Neuropharmacology 12:853–866Google Scholar
  55. Vaccarino FJ, Amalric M, Swerdlow NR, Koob GF (1986) Blockade of amphetamine but not opiate induced locomotion following antagonism of dopamine function in the rat. Pharmacol Biochem Behav 24:61–65Google Scholar
  56. Versteeg DHG, Van der Gugten J, De Jong WS, Palkovits M (1976) Regional concentrations of noradrenaline and dopamine in rat brain. Brain Res 113:563–574Google Scholar
  57. Yamamoto JK, Spanos LJ (1988) The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 148:195–203Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Lisa H. Gold
    • 1
  • Carol B. Hubner
    • 1
  • George F. Koob
    • 1
  1. 1.Department of Basic and Clinical ResearchResearch Institute of Scripps ClinicLa JollaUSA

Personalised recommendations